Company: STAA
Filing Date: 2025-10-07
Form Type: PX14A6G
Source: 0001193125-25-232531
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-10-07
Form: PX14A6G
Chunk 1
---
7, 2025

Dear Fellow STAAR Surgical Shareholders:

After reviewing the
recent public communications from STAAR, including STAAR’s investor presentation issued on September 26, 2025, titled “Alcon Merger Maximizes Value for Stockholders – STAAR Surgical – September 2025” (the
“STAAR Investor Presentation”) and its two press releases of October 6, 2025, we feel compelled to reiterate our opposition to the proposed sale to Alcon.

Shareholders deserve better. We believe the Company is significantly underestimating the strength of its business – particularly with respect to its
performance and outlook in its largest market, China. Several of our views on certain of these critical issues are shared by Broadwood Partners in its investor presentation issued on October 2, 2025, titled “The Wrong Time, Wrong Process and Wrong Price.”

As an investor in STAAR that has met with the Company’s Board and management several times over the past years
to share our insights on the Chinese market and how the Company can drive future growth, we believe that many statements in the Company’s presentation may distort shareholders’ appreciation of STAAR’s actual long-term value. The
China market is recovering, STAAR has the trusted products and established sales channels to capitalize on this large and growing opportunity, and Alcon’s bid for STAAR is clearly opportunistic.

As experienced investors in China, we have a deep understanding of Chinese market dynamics and disagree with the pessimistic outlook that STAAR has
consistently presented to investors since rolling out the proposed merger. Our concerns pertain especially to the Company’s comments regarding the strength and intrinsic value of its Implantable Collamer Lens (“ICL”) technology,
its deep-rooted global market position, and its significant operational potential.

STAAR’s Recent Operating and Financial Performance Is More Transitory Than STAAR Admits, and STAAR Fails to Be Upfront About the Temporary Nature of Challenges in China

STAAR’s recent presentation claims that “STAAR’s operating and financial results over the last several years have been inconsistent and impacted by challenges facing the business, which has led to stock price declines.”(STAAR Investor Presentation, page 6)

STAAR has repeatedly pointed to recent “inconsistent” performance results as a justification for the current proposed merger, but STAAR
conveniently ignores the temporary nature of recent headwinds, particularly in China. From 2023 actuals to 2025 estimates, the approximately 10%